美德纳Moderna（MRNA）2024年年度报告「NASDAQ」（英文版）（176页）.pdf

1、2024annual report*as of December 31,2024 Moderna by the Numbers*Delivering commercial impact$3.1Bnet product sales3biologics license applications filedCelebrating our culture10years as a Science Top Employer3rdconsecutive year of equal pay for equal work study showing no statistically significant di

2、fferences inpayNo.1ranked large company in BioSpace Best Places to WorkAdvancing our pipeline$9.5Bcash,cash equivalents andinvestments2approved products4therapeutic areas41programs in clinical trialsDigitizing everywhere4,500monthly active ChatGPT Enterprise users1,600custom GPTs in use1 million mes

3、sages a month withChatGPT Enterprise1Moderna 2024 Annual ReportTable of ContentsManufacturingPipelineRespiratory FranchiseDigitizing EverywherePeople andCultureResponsibilityLeadershipAwards and recognitionFinancialsA Letter from Our CEOTable of Contents3 A Letter from Our CEO10 Respiratory Franchis

4、e12 Pipeline15 Manufacturing17 Digitizing Everywhere18 People and Culture20 Responsibility22 Leadership23 Awards and Recognition Highlights24 Financials2Moderna 2024 Annual ReportTable of ContentsManufacturingPipelineRespiratory FranchiseDigitizing EverywherePeople andCultureResponsibilityLeadership

5、Awards and recognitionFinancialsA Letter from Our CEOA Letter from Our CEOJanuary 6,2025Dear fellow shareholders,As we reflect on 2024,it is clear that the past year brought formidable challenges for Moderna along with significant advances,particularly for our development pipeline.It was a year of n

6、avigating a dynamic global landscape and evolving commercial realities,demanding resilience,innovation andadaptability.The shifting dynamics of the COVID and RSV vaccine markets tested our commercial strategies and required us to reassess our financial framework.These challenges underscored the comp